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LymphomaAbstract Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that promotes
tumorigenesis by epigenetic repression of tumor suppressor genes. Although EZH2 is
overexpressed in many malignancies, activating EZH2 mutations have been described
predominantly in follicular lymphoma and diffuse large B-cell lymphoma. EZH2 activating
mutations in melanoma are not well described. Here, we report a case of cutaneous melanoma that
displayed an EZH2 (Y641S) activating mutation detected by transcriptome sequencing as well as
BRAF (V600K). The patient had concurrent follicular lymphoma that lacked both the EZH2
(Y641) and BRAF (V600K) mutations present in the patient's melanoma. Further, we screened
publicly available sequence data and identified four additional melanoma cases harboring
activating EZH2 mutation. Our findings provide additional evidence that activating recurrent
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22 P.W. Harms et al.harbor such mutations. These tumors may be amenable to EZH2 inhibitor therapy.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction Here, we report an activatingmutation of EZH2 at Y641 inMalignant melanoma is responsible for the majority of
skin-cancer related deaths [1]. For patients with metastatic
disease, the prognosis is very poor with median survival of
6–9 months [2]. Therapeutic options for patients with stage
III and IV disease remain limited; however, advances in
targeted therapy appear promising. For example, approxi-
mately 50% of cutaneous melanomas contain an activating
missense mutation in BRAF at valine 600 [2]. While many
patients initially respond well to BRAF inhibitors, the
response is not durable due to tumor resistance [2–4].
Targeting of the receptor tyrosine kinase KIT has shown
mixed results [5]. More recently, immunity-associated
therapies such as ipilimumab and nivolumab have shown
some promise. It is clear that identification of additional
actionable oncogenes in melanoma is necessary. However,
the high burden of ultraviolet-associated mutations in many
melanomas poses a challenge, making it difficult to
distinguish driver mutations from passengermutations [5–9].
In addition to genetic aberrations, growing evidence has
revealed significant involvement of epigenetic modifica-
tions in tumorigenesis.Mechanisms of epigenetic regulation
include histone methylation, acetylation, phosphorylation,
and ubiquitylation, as well as DNA methylation. Enhancer
of zeste homolog 2 (EZH2) is a histone methyltransferase
that is the catalytic core of the polycomb repressive complex
2 (PRC2). In this context, EZH2 epigenetically silences
multiple tumor suppressor genes via inhibitory trimethyla-
tion of lysine 27 on histone H3 (H3K27me3). Thus,
overexpression or activating mutations of EZH2 are
postulated to promote tumorigenesis by inactivating tumor
suppressor genes, although additional oncogenic activities
for EZH2 have also been proposed [10].
Consistent with its demonstrated oncogenic activity,
EZH2 is overexpressed in cancers and has been linked to
a poor prognosis in melanoma as well as breast and
prostate carcinoma [11–14]. Gain-of-function missense
mutations of EZH2 at tyrosine 641 (Y641) have been
identified in follicular lymphoma and diffuse large B-cell
lymphoma. These mutations lead to an increased EZH2
stability and an increase in H3K27 trimethylation
[10,15–17]. Recently, activating EZH2 (Y641) muta-
tions have also been reported in two cases of melanoma
as part of a larger next-generation sequencing study [18].
Importantly, EZH2 inhibitors are under active investiga-
tion in clinical trials as potential therapeutic agents in
lymphoid malignancies [10,19].a case of metastatic melanoma identified by transcriptome
sequencing. This case also harbored an activating BRAF
V600K mutation. Screening of publicly available sequence
data identified four additional, previously unreported mela-
noma cases harboring activating EZH2 mutation. The finding
of activatingmutations in EZH2 further supports an oncogenic
role for EZH2 in melanoma and suggests that EZH2 may
represent a therapeutic target in a subset of melanomas.2. Methods
2.1. Tumor samples
All human subject studies were approved by the
Institutional Review Board of the University of Michigan.
All tumor tissue was procured from the University of
Michigan Hospitals Cutaneous Surgery and Oncology
Program with appropriate informed consent. A punch biopsy
was obtained from subjects, bisected and one half flash-frozen
in liquid nitrogen. The opposing half of the tissue punch was
processed for hematoxylin and eosin (H&E) staining to
confirm tumor purity. Specimens with adequate tumor purity
were stored at −80 °C until RNA or DNA extraction.2.2. Transcriptome sequencing
Total RNA was isolated from tissue samples with Trizol
and RNeasy kit (Qiagen). RNA quality was verified by
Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto,
CA). polyA + RNA was purified from 2–3 micrograms of
total RNA using SeraMag oligo-dT magnetic bead selection
(Thermo Scientific). Library construction was performed as
previously described [20,21]. Paired-end transcriptome
sequencing was performed on an Illumina HiSeq 2000.
Sequence analysis was performed using the previously
described bioinformatics pipeline, including sequencing read
alignment by TopHat and ab initio assembly by Cufflinks.2.3. DNA extraction from formalin-fixed
paraffin-embedded tissue
Formalin-fixed paraffin-embedded (FFPE) tissue was
obtained from archival tissue blocks. For melanoma, tumor
purity was determined by review of H&E stained and
Melan-A immunostained slides by two pathologists with
23Oncogenic activation of EZH2 in melanomadermatopathology subspecialty training (PWH and ACH).
For lymphoma, tumor purity was determined by review of
H&E stained and BCL-2 immunostained slides by a
pathologist with hematopathology subspecialty training
(ACH). Using a guide H&E stained slide, FFPE material
was macrodissected from an area of N90% tumor using a
sterile scalpel. After xylene deparaffinization, genomic
DNA was extracted by DNeasy kit according to manufac-
turer's protocols (Qiagen).2.4. Reverse transcription, PCR and
Sanger sequencing
Reverse transcription of tumor RNA was performed
using Superscript II reverse transcriptase according to
manufacturer's protocols. PCR was performed on Eppen-
dorf Mastercycler thermocycler using Platinum Taq DNA
polymerase (Life Technologies), according to manufac-
turer's instructions. PCR products were purified using
Qiaquick PCR purification kit or by agarose gel separation
and band purification using Qiaex II beads (Qiagen).
Sanger sequencing was performed at the University of
Michigan DNA Sequencing Core according to standard
Core protocols on an ABI Model 3730XL sequencer.Fig. 1 Morphologic and immunohistochemical features of melanom
with scattered mitotic figures form sheets and vague aggregates; lympho
shows tumor cells with faint cytoplasmic pigmentation and intermi
highlighted by Melan-A immunohistochemical staining (×400).Primers for cDNA and genomic DNA [22,23] are listed in
Supplemental Table S1.
2.5. Immunohistochemistry
Immunohistochemistrywas performed onVentanaBench-
mark automated stainer according to manufacturer's proto-
cols. Antibodies used for immunohistochemistry are listed in
Supplemental Table S2. Photomicrographs were obtained
using an Olympus DP72 camera mounted on an Olympus
BX41microscope andCellSens software. Immunohistochem-
istry for EZH2 has been previously described [11].3. Results
The index case was a 40 year-old woman who
developed a cutaneous melanoma with Breslow depth
N20 mm on her back. She presented to the University of
Michigan for further evaluation and treatment. University
of Michigan review of the outside pathology confirmed
that the melanoma was positive for S100 and HMB-45 at
the time of diagnosis. In addition, the melanoma expressed
Melan-A (Fig. 1). The patient had palpable axillary lympha metastatic to soft tissue. A) Frankly malignant, epithelioid cells
cytes are not conspicuous (H&E, ×400). B) Higher magnification
xed melanophages (H&E, ×600). C) The malignant cells are
Fig. 2 Morphologic and immunohistochemical features of follicular lymphoma. A) Low magnification shows lymph node effacement
by abnormal, closely-packed follicle structures (H&E, ×100). B) On higher magnification, abnormal follicles are predominantly
composed of centrocytic cells, with few scattered centroblasts; they lack appropriate polarization and tingible body macrophages (H&E,
×400). C) Abnormal follicles are highlighted by BCL2 (×100). D) No Melan-A positive cells are identified (×100).
24 P.W. Harms et al.nodes that were positive for melanoma by fine needle
aspiration.
During the course of clinical workup, an abdominal
mass was identified. Core biopsy of the mass demonstrated
small B lymphocytes with nuclear clefts. Flow cytometry
revealed a monoclonal population of B-cells that expressed
CD20, CD19, CD10 (dim) and lambda. These findings
were consistent with a low-grade follicular lymphoma.
Management of the melanoma included wide local
excision and axillary lymph node dissection that revealed
lymph nodes with metastatic melanoma, follicular lym-
phoma, or both (Fig. 2). In addition, multiple soft tissue
melanoma metastases were identified (Fig. 1). During this
surgical management of the patient's melanoma, the
patient was consented and two samples from melanoma
metastases were collected according to standard protocols
at the University of Michigan Hospitals Cutaneous
Surgery and Oncology Program. The patient's melanoma
followed a rapidly aggressive course, with radiologic
evidence of melanoma metastases to bilateral lungs,
spleen, and liver appearing two months after lymph node
dissection. Because vemurafenib was not in widespread
use at the time, the patient's melanoma was not clinically
tested for BRAF mutation. She was managed with
rituximab for follicular lymphoma, and chemotherapy formetastatic melanoma. However, her metastatic melanoma
continued to progress. She died of disease 7 months after
the initial excision of her primary melanoma.
One soft tissue metastasis with high-quality RNA was
analyzed by transcriptome sequencing. Sequencing data
was filtered for single nucleotide variations with at least 5
supporting reads of genes in the Cancer Gene Census for
somatic mutations (http://cancer.sanger.ac.uk/cosmic/
census). Using these criteria, 20 non-synonymous single
nucleotide variations in Cancer Census genes were
identified (Supplementary Table S3). Of these, the
majority (19/20) represented single nucleotide polymor-
phisms reported in dbSNP and were excluded from further
analysis. The remaining mutation was an A to C
transversion resulting in a Y641S missense mutation of
EZH2. Variant reads represented 38% (5/13) of total reads
at this position, consistent with a heterozygous mutation.
PCR amplification and Sanger sequencing of exons 15–
20 of EZH2 from tumor cDNA confirmed the presence of a
heterozygous single nucleotide variation at Y641S
(Fig. 3A). Due to insufficient coverage of BRAF codon
600 in the sequencing data, PCR amplification and Sanger
sequencing of BRAF exons 13–16 were performed on
tumor cDNA and demonstrated a V600K mutation
(Fig. 3B).
Fig. 3 EZH2mutational status and expression in index case. A) Sanger sequencing chromatogram of heterozygous A to Cmutation resulting in
EZH2 (Y641S) mutation. B) Sanger sequencing chromatogram of GT to AA mutation resulting in BRAF (V600K) mutation. C) Transcript
expression of EZH2 in index case relative to other melanoma tumors inMichigan Center for Translational Pathology sequencing compendium. D)
Protein expression of EZH2 in index case by immunohistochemistry (400× magnification).
25Oncogenic activation of EZH2 in melanomaTranscriptome sequencing allows for comparison of
transcript expression levels across tumor cohorts. The index
case displayed the highest expression of EZH2 transcript
relative to othermelanoma tumors in theMichigan Center for
Translational Pathology sequencing compendium (Fig. 3C).
Retrospective review of EZH2 immunohistochemical stain-
ing performed as part of a previous study [11] identified
EZH2 protein expression in the index case (Fig. 3D).
Given that activating EZH2 mutations have also been
described in follicular lymphoma, we analyzed the patient's
follicular lymphoma for BRAF and EZH2. Due to lack of
frozen material from the lymphoma, we performed PCR
amplification and Sanger sequencing of BRAF (V600) and
EZH2 (Y641) using DNA from FFPE of lymphoma tissue
collected during axillary node dissection (Fig. 2). No
mutationwas identified in either gene (Supplementary Figure
S1). Similar analysis of DNA extracted from FFPE material
of the patient's melanoma confirmed the EZH2 and BRAF
mutations identified by sequence analysis (not shown).
To further confirm that the sample harboring the EZH2
and BRAF mutations was derived from melanoma, we
examined expression of melanocytic markers and B-cell
markers in the tumor specimen relative to other tumors in the
Michigan Center for Translational Pathology compendium.
As expected, the index case expressed melanocytic markersMLANA, PMEL, and MiTF at similar levels to other
melanomas (Supplemental Figure S2A-C). In contrast, there
was no significant expression of lymphoid markers CD20
(MS4A1), CD79A, and PAX5 (Supplemental Figure S2D-F).
To evaluate the frequency of EZH2 mutation in
melanoma, we next analyzed cDNA from 125 melanoma
samples (105 frozen tumor and 20 cell lines) for the Y641
mutation by PCR amplification and Sanger sequencing of
EZH2 exons 15–20. This cohort included a second distinct
metastatic melanoma sample collected at a separate time
from the index patient, which was interpreted in a blinded
manner and verified to harbor the EZH2 (Y641) mutation.
The melanoma cell line WM-1366 was found to harbor a
previously unreported mutation in EZH2 at Q735R. The
significance of this mutation is unknown. No EZH2 (Y641)
mutations were identified in the additional samples.
To determine the frequency of EZH2 mutations in
melanoma, we queried publicly available sequencing data
through the cBioPortal database (http://www.cbioportal.
org) that contains 475 cases from published melanoma
sequencing studies [9,18] as well as The Cancer Genome
Atlas melanoma cohort. 18 missense mutations in EZH2
were identified, of which 6 occurred at Y641 codon
(Table 1). Two of these cases have previously been
reported in the literature [18], whereas the remaining four
Table 1 Spectrum of EZH2 missense mutations in melanoma.
Study Sample ID EZH2 BRAF NRAS
TCGA TCGA-D9-A1JW Y641F N581T WT
TCGA TCGA-EE-A3AF Y641N V600E WT
TCGA TCGA-FS-A1ZC T4L V600K WT
TCGA TCGA-D3-A3ML P132S WT Q61l
TCGA TCGA-EE-A2A0 D142V L597Q, P367S WT
TCGA TCGA-EE-A2GC R216Q G466E WT
TCGA TCGA-ER-A1A1 A226V WT WT
TCGA TCGA-EE-A180 P426S WT WT
TCGA TCGA-EE-A2M5 C530W V600E WT
TCGA TCGA-FR-A3YN S533L WT Q61R
Krauthammer et al. [9] YUPAT Y641N WT WT
Krauthammer et al. [9] YUKIL Y641N V600E WT
Krauthammer et al. [9] YUPAT S229L WT WT
Krauthammer et al. [9] YULAPE R342Q WT Q61H
Hodis et al. [18] ⁎ MEL-JWCI-WGS-25 Y641F V600K WT
Hodis et al. [18] ⁎ MEL-13456 Y641S V600E WT
Hodis et al. [18] ⁎ MEL-JWCI-WGS-42 R34P V600E WT
Hodis et al. [18] ⁎ MEL-JWCI-WGS-25 I645 (splice) V600K WT
Hodis et al. [18] ⁎ MEL-Ma-Mel-114 P746S WT WT
Current study MEL56 Y641S V600K WT
Current study WM-1366 Q735R ND ND
EZH2, BRAF, and NRAS missense mutations were compiled by querying the indicated sequencing study via the cBioPortal database. Mutations
identified in the current study by transcriptome sequencing (MEL56) or direct sequencing (WM-1366) are included for reference. TCGA: The Cancer
Genome Atlas.
⁎ EZH2 mutations previously reported by Hodis et al. [18].
26 P.W. Harms et al.were previously unknown. Similar to our case, EZH2
(Y641) mutation was accompanied by BRAF (V600)
mutation in 4/6 (67%) of cases. One additional case
displayed a BRAF (N581) missense mutation that has been
previously reported in melanoma [24] but to our knowl-
edge has not been functionally characterized.4. Discussion
EZH2 is a histone methyltransferase that has been
implicated in both hematologic and solid malignancies.
Overexpression of EZH2 has been linked to poor outcome
in melanoma as well as other cancers including breast and
prostate carcinoma [13,14]. Heterozygous somatic mis-
sense mutations at EZH2 codon Y641 (EZH2 Refseq
isoform C, NM_001203247), also reported as Y646
(EZH2 Refseq isoform A, NM_004456), have been
identified in follicular lymphoma and diffuse large B cell
lymphoma [10,15]. EZH2 (Y641) missense mutations
result in increased EZH2 stability and increased
H3K27me3 activity, resulting in the repression of tumor
suppressor genes [16,17]. Interestingly, a minority of
myeloid dysplasia syndromes/myeloproliferative neo-
plasms display inactivating EZH2 mutations, indicatingthat EZH2 may play distinct roles in neoplasia depending
on cell type [10].
Mounting evidence supports an oncogenic role for
EZH2 in melanoma. EZH2 depletion in cultured melano-
ma cells results in p21/CDKN1A upregulation, decreased
invasion, decreased proliferation and a shift toward
cellular senescence [25–27]. EZH2 expression increases
with neoplastic progression in melanocytic lesions [28],
and overexpression is associated with poor prognosis in
melanoma [11,12]. In a subset of melanomas, EZH2
overexpression may be related to loss of tumor suppressive
microRNAs including miR-31, which downregulate EZH2
expression [11].
To our knowledge, melanoma is the first solid tumor
for which EZH2 (Y641) activating mutations have been
described, with two cases in the literature [18]. We
identified one additional case of melanoma with EZH2
(Y641) mutation by transcriptome sequencing, and found
four additional cases in publicly available sequencing
datasets. Although our patient had a concomitant lympho-
ma, only the melanoma tumor harbored the activating
mutation of EZH2. This is supported by melanocytic but
not lymphoid marker expression in the tumor sample
harboring the EZH2 mutation. In addition, the BRAF
V600K mutation was also identified in our sample with
EZH2 (Y641) mutation. BRAF mutations are well known
27Oncogenic activation of EZH2 in melanomain melanoma but have not been identified in follicular
lymphoma to our knowledge. Furthermore, the identical
EZH2 mutation was also detected in a separate frozen
sample of metastatic melanoma from the same patient as
well as melanoma tumor DNA extracted from an archival
FFPE block. In contrast, the patient's follicular lymphoma
demonstrated neither EZH2 (Y641) nor BRAF (V600)
mutations. Transdifferentiation of lymphoma into Langer-
hans cell neoplasms, histiocytic sarcomas and dendritic
cell sarcomas has been reported [29,30]. However, the
expression of melanocytic markers including Melan-A in
the index case, together with the lack of shared EZH2 and
BRAF mutations between the melanoma and lymphoma,
makes transdifferentiation unlikely in this case.
To our knowledge, there is currently no mutation-
specific antibody for EZH2 (Y641). The observation that
EZH2 protein was overexpressed in our index case,
together with the recent report that EZH2 (Y641)
increases protein stability [17], raises the question whether
immunohistochemistry for EZH2 expression might be a
useful screen for detecting melanomas harboring EZH2
(Y641). To address this possibility, we reviewed previ-
ously performed EZH2 immunohistochemistry results
[11] corresponding to a subset of melanoma cases
characterized for EZH2 mutation status by Sanger
sequencing in the current study. Although all but one
sample lacked EZH2 (Y641) mutation, most melanomas
(30/46, 65%) displayed moderate to strong EZH2 protein
expression in the majority of tumor cells (data not shown).
Therefore, in most melanomas EZH2 overexpression is
likely mediated by alternative mechanisms such as loss of
regulatory miRs [11].
Taken together with previous functional studies
supporting an oncogenic role for EZH2 in melanoma,
the observation of activating oncogenic mutations further
underscores the importance of EZH2 in melanoma
biology. Although the sample size is small, it appears
that EZH2 (Y641) mutations are frequently associated
with BRAF mutations, raising the possibility for syner-
gistic roles of EZH2 and BRAF in melanoma. Therapies
targeting BRAF and EZH2 were not attempted in our
index case because these were not in widespread use at the
time. Therefore, additional study is needed regarding
whether concurrent EZH2 activation affects response to
BRAF inhibitor therapy.
Together with the previous report [18] and examination
of publicly available sequence data, our results indicate
that EZH2 activating mutations are relatively rare in
melanoma, occurring in approximately 1% of cases.
Additional cases of melanoma with activating EZH2
mutations may be uncovered in the future by next-
generation sequencing as applied to personalized medicine,
and further investigation is needed to determine whether
therapeutic targeting of EZH2 may be useful in this setting.Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ehpc.2014.07.002.Acknowledgments
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